Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials

by Jakub Jedynak, Eric Eross, Astrid Gendolla, Mallikarjuna Rettiganti, Virginia L. Stauffer
Published 2021-05-01

Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)

by Stephen D. Silberstein, Virginia L. Stauffer, Katie A. Day, Sarah Lipsius, Maria-Carmen Wilson
Published 2019-06-01

Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)

by Stephen D. Silberstein, Virginia L. Stauffer, Katie A. Day, Sarah Lipsius, Maria-Carmen Wilson
Published 2019-12-01

Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1,...

by Stefanie Förderreuther, Qi Zhang, Virginia L. Stauffer, Sheena K. Aurora, Miguel J. A. Láinez
Published 2018-12-01

Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine

by Michael Ament, Kathleen Day, Virginia L Stauffer, Vladimir Skljarevski, Mallikarjuna Rettiganti, Eric Pearlman, Sheena K. Aurora
Published 2021-02-01

Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine

by Michael Ament, Kathleen Day, Virginia L. Stauffer, Vladimir Skljarevski, Mallikarjuna Rettiganti, Eric Pearlman, Sheena K. Aurora
Published 2021-08-01

Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine

by Virginia L. Stauffer, Shufang Wang, Jo Bonner, ByungKun Kim, Rohit Bhandari, Kathleen A. Day, Angelo Camporeale
Published 2020-05-01

Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials

by Virginia L. Stauffer, Ira Turner, Phebe Kemmer, William Kielbasa, Kathleen Day, Martha Port, Tonya Quinlan, Angelo Camporeale
Published 2020-06-01

A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

by Angelo Camporeale, David Kudrow, Ryan Sides, Shufang Wang, Annelies Van Dycke, Katherine J. Selzler, Virginia L. Stauffer
Published 2018-11-01

Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies

by Mark E. Bangs, David Kudrow, Shufang Wang, Tina M. Oakes, Gisela M. Terwindt, Delphine Magis, Laura Yunes-Medina, Virginia L. Stauffer
Published 2020-01-01

Correction to: Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies

by Mark E. Bangs, David Kudrow, Shufang Wang, Tina M. Oakes, Gisela M. Terwindt, Delphine Magis, Laura Yunes-Medina, Virginia L. Stauffer
Published 2020-03-01